AF
BCTX

Allworth Financial’s Briacell Therapeutics BCTX Stock Holding History

Allworth Financial’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$419 Hold
100
– – ﹤0.01% 4773
2025
Q4 		$711 Buy
100
+93
+1,329% +$981 ﹤0.01% 4456
2025
Q3 		$77 Hold
7
– – ﹤0.01% 4707
2025
Q2 		$206 Buy
+7
New +$255 ﹤0.01% 4313

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Allworth Financial's BCTX Position: Q1 2026 in Review

Allworth Financial held its Briacell Therapeutics (BCTX) position steady in Q1 2026 at 100 shares worth $419. The position accounts for ﹤0.01% of the portfolio, ranked #4773.

Allworth Financial first reported a position in BCTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $711 in Q4 2025. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Allworth Financial held 100 shares of Briacell Therapeutics worth $419 as of Q1 2026.
  • Allworth Financial left its Briacell Therapeutics share count unchanged in Q1 2026.
  • Briacell Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4773 holding.
  • Allworth Financial first reported a position in Briacell Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Allworth Financial's Briacell Therapeutics position peaked at $711 in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.